Evidence map›Paper›PMID 40314902›Full record

ArticleAnnals of surgical oncology2025

Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens.

Yosuke Inoue, Manabu Takamatsu, Yohei Masugi, Tatsunori Suzuki, Tsuyoshi Hamada, Satoru Abe, Kensuke Hara, Yoshikuni Kawaguchi, Kosuke Kobayashi, Aya Maekawa and 13 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yosuke Inoue *Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Manabu Takamatsu *Division of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Yohei Masugi *Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
Tatsunori Suzuki *Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tsuyoshi HamadaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. hamada-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-3937-2755
Satoru AbeHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kensuke HaraDepartment of Pathology, Keio University School of Medicine, Tokyo, Japan.
Yoshikuni KawaguchiHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kosuke KobayashiDepartment of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Aya MaekawaDepartment of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yousuke NakaiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Naoki SasahiraDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tsuyoshi TakedaDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Mariko TanakaDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yosuke UematsuDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Sho UemuraDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kengo TakeuchiDivision of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan.
Minoru Kitago *Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Kiyoshi Hasegawa *Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yu Takahashi *Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
GTK Pancreatic Cancer Study Group in Japan

Funding

Daiwa Securities Health Foundation Not availableJapan Agency for Medical Research and Development JP21ck0106557Japan Society for the Promotion of Science JP20K07414Japan Society for the Promotion of Science JP21K15368Japan Society for the Promotion of Science JP21K15393Japan Society for the Promotion of Science JP22H02841Japan Society for the Promotion of Science JP23K15485Okinaka Memorial Institute for Medical Research Not availablePancreas Research Foundation of Japan Not availableTakeda Science Foundation Not availableVehicle Racing Commemorative Foundation Not available
6 · The paper itself

Abstract

backgroundFew comprehensive studies have examined the associations of the ABO blood group with survival outcomes for patients with resected pancreatic cancer, overall and by adjuvant chemotherapy regimens.

methodsThis multicenter study enrolled 1153 patients with resected pancreatic cancer. The hazard ratios (HRs) for disease-free and pancreatic cancer-specific survival were calculated with adjustment for potential confounders, including KRAS mutation and CDKN2A (p16), TP53, and SMAD4 expression, using the Cox proportional hazards regression model. Blood group antigen expression in tumors was immunohistochemically assessed.

resultsThe ABO blood group was not associated with disease-free or pancreatic cancer-specific survival (P > 0.90). For pancreatic cancer-specific survival, blood groups A, B, and AB had multivariable HRs of 0.97 (95% confidence interval [CI], 0.81-1.15), 1.03 (95% CI, 0.83-1.26), and 0.99 (95% CI, 0.76-1.30), respectively (vs. O). The associations between ABO blood group and disease-free and pancreatic cancer-specific survival differed according to the adjuvant chemotherapy regimens (P

conclusionsThe ABO blood group is not a prognostic biomarker in resected pancreatic cancer overall but may predict the effectiveness of adjuvant chemotherapy.

Indexed as

ABO Blood-Group SystemAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorPancreatic NeoplasmsAdultAgedCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPancreatectomyPrognosisABO Blood-Group SystemBiomarkers, TumorBlood group antigensCohort studiesMortalityPancreatectomyPancreatic ductal adenocarcinoma

Identifiers

PMID40314902
PMCPMC12317920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.